Dr. Parti, who joined KGI in August 2016, has spent more than two decades of his career working in the biotech industry. He started his career at Baxter in the R & D department where he worked on developing new formulations for recombinant and plasma derived protein therapeutics. Following R & D, he switched to Quality Operations and lead the stability operations group at Baxter. He was responsible for stability studies for various biologics indicated for use in Bleeding Disorders, Neurological diseases, Critical care and Oncology. He then moved to Post-Market Surveillance group at Baxter/Baxalta and was involved in pharmacovigilance and drug safety activities.
At KGI, he is part of the Bioprocessing group and teaches topics in Quality and Regulatory to the Master of Engineering (MEng) in Biopharmaceutical Procesing students. Dr. Parti holds a PhD in Pharmaceutical Sciences from University of Southern California and a MS degree in Pharmaceutical Sciences from Wayne State University, Detroit.